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Summary
Background The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and 
the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the 
cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We 
also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated 
with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. 
Methods In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium 
data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular 
disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary 
composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart 
disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol 
categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable 
cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a 
cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated 
modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol.
Findings Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals 
belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7–59·7]). 199 415 individuals were 
included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation 
cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0–20·1), 54 542 cardiovascular 
endpoints occurred. Incidence curve analyses showed progressively higher 30-year cardiovascular disease event-
rates for increasing non-HDL cholesterol categories (from 7·7% for non-HDL cholesterol <2·6 mmol/L to 33·7% 
for ≥5·7 mmol/L in women and from 12·8% to 43·6% in men; p<0·0001). Multivariable adjusted Cox models with 
non-HDL cholesterol lower than 2·6 mmol/L as reference showed an increase in the association between non-HDL 
cholesterol concentration and cardiovascular disease for both sexes (from hazard ratio 1·1, 95% CI 1·0–1·3 for non-
HDL cholesterol 2·6 to <3·7 mmol/L to 1·9, 1·6–2·2 for ≥5·7 mmol/L in women and from 1·1, 1·0–1·3 to 2·3, 
2·0–2·5 in men). The derived tool allowed the estimation of cardiovascular disease event probabilities specific for 
non-HDL cholesterol with high comparability between the derivation and validation cohorts as reflected by smooth 
calibration curves analyses and a root mean square error lower than 1% for the estimated probabilities of 
cardiovascular disease. A 50% reduction of non-HDL cholesterol concentrations was associated with reduced risk of 
a cardiovascular disease event by the age of 75 years, and this risk reduction was greater the earlier cholesterol 
concentrations were reduced.
Interpretation Non-HDL cholesterol concentrations in blood are strongly associated with long-term risk of 
atherosclerotic cardiovascular disease. We provide a simple tool for individual long-term risk assessment and the 
potential benefit of early lipid-lowering intervention. These data could be useful for physician–patient communication 
about primary prevention strategies.
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Introduction
Numerous studies have provided consistent evidence for 
a causal relationship between blood cholesterol concen­
trations and cardiovascular disease.1,2 Calculating the 
concentration of non­HDL cholesterol offers a simple 
way to analyse the total amount of proatherogenic 
lipoproteins containing apolipoprotein B (apoB).3 Such 
proteins include very low­density lipoproteins and their 
metabolic remnants, intermediate­density lipoproteins, 
lipoprotein(a), and low­density lipoproteins.3 Besides 
estimating cholesterol concentrations contained in LDL 
particles (LDL cholesterol), the assessment of non­HDL 
cholesterol calculated as total cholesterol minus HDL 
cholesterol is therefore recommended by current US and 
European guidelines for cardiovascular risk estimation.4,5 
The indication for lipid­lowering therapy to prevent car­
diovascular disease events in high­risk individuals or 
for secondary prevention is unequivocal.4–9 However, the 
decision on implementing a lipid­lowering intervention 
in the primary prevention setting is a major challenge 
in clinical practice for several reasons. Data on the 
association between the concentrations of the entire 
range of bloodstream lipids and very long­term cardio­
vascular outcomes in the general population are rather 
sparse.10,11 In addition, conventional primary prevention 
guidelines recommend lipid­lowering inter vention on 
the basis of lipid concentration thresholds and the 
person’s individual 10­year cardiovascular risk.4,5 This 
risk assessment might underestimate or fail to take 
proper account of the cumulative lifetime risk of 
cardiovascular disease and lipid­related cardiovascular 
disease risk, par ticularly in young adults.12 Furthermore, 
increased non­HDL cholesterol blood concentrations 
early in life seem to be stable over the life course and are 
predictive for incident cardiovascular disease.13 Therefore, 
in this study we aimed to (1) evaluate long­term risk 
for cardiovascular disease in the population related to 
non­HDL cholesterol on the basis of existing thresholds 
of blood lipid concentrations; (2) establish an easily 
applicable tool to assess the long­term probabilities for 
cardiovas cular disease events associated with non­HDL 
choles terol, using a derivation and validation approach; 
and (3) provide a model indicating the potential benefit 
of an early lipid­lowering strategy in individuals without 
prevalent cardiovascular disease.
Methods
Study design and participants
In this risk­evaluation and risk­modelling study, we used 
individual­level data from the Multinational Cardiovascular 
Risk Consortium (appendix pp 2–11). Currently, the 
Consortium comprises data on 524 444 individuals from 
44 population­based co horts across Europe, Australia, and 
the USA. These include 23 harmonised cohorts from 
the MONICA Risk Genetics Archiving and Monograph 
(MORGAM)14 and Biomarker for Cardiovascular Risk 
Assessment in Europe (BiomarCaRE)15 studies and another 
21 harmo nised, population­based cohorts with the same 
Research in context
Evidence before this study
The blood concentrations of non-HDL and LDL cholesterol are 
accepted as causal cardiovascular risk factors and constitute a 
cornerstone of cardiovascular disease risk prediction in the 
general population. The benefit of lipid-lowering interventions 
for cardiovascular disease risk reduction is proven by mendelian 
randomisation studies, prospective epidemiological cohort 
studies, and randomised trials. For the present study, we assessed 
recommendations made by the European and US guidelines and 
their underlying references for lipid-lowering strategies in 
primary prevention. Furthermore, we reviewed the cardiovascular 
risk calculators as recommended by these guidelines (Systematic 
COronary Risk Evaluation [SCORE] and Pooled Cohort Equations). 
We found very little data describing the effect of baseline non-
HDL and LDL cholesterol on long-term or even lifetime outcomes. 
Cardiovascular risk assessment was mainly based on 10-year 
medium-term follow-up. All identified randomised trials for 
lipid-lowering intervention in cardiovascular primary prevention 
did not exceed a follow-up of 7 years and, moreover, especially 
young individuals were underrepresented in those studies.
Added value of this study
To our knowledge, our study provides the most comprehensive 
analysis of long-term risk for cardiovascular disease related to 
non-HDL cholesterol and offers an easily applicable tool to 
assess the long-term probabilities for cardiovascular disease 
events associated with non-HDL cholesterol. On the basis of a 
derivation and validation approach to risk prediction, our data 
provide robust multinational information. By using an 
up-to-date multinational population-based pooled cohort 
dataset, we provide a model that calculates the potential benefit 
of an early lipid-lowering strategy in individuals without 
prevalent cardiovascular disease across a range of non-HDL 
cholesterol categories.
Implications of all the available evidence
There is evidence for the positive outcomes in lipid-lowering 
interventions in individuals with cardiovascular disease or those 
with very high cholesterol concentrations. Our data extend 
current knowledge and highlight the impact of non-HDL 
cholesterol on very long-term cardiovascular disease outcomes. 
A simulation of early reduction of non-HDL cholesterol across a 
range of lipid concentration categories estimates the risk 
reduction in the general population. Meeting targets for global 
reduction of cardiovascular disease morbidity and mortality will 
require increased awareness of the value of early cholesterol 
determination and careful evaluation of potential strategies for 
reduction of lipid concentrations across the lifespan.
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specifi cations as defined for the BiomarCaRE and 
MORGAM projects (appendix pp 15–18). Of these, we used 
cohorts that had available data on cardiovascular disease 
end points (appendix pp 16–18). We excluded data on 
participants with prevalent cardiovascular disease, defined 
as a history of myocardial infarction, coronary artery 
bypass grafting, percuta neous transluminal coronary 
angioplasty, or ischaemic or haemorrhagic stroke. Detailed 
information about the study cohorts including the number 
of individuals with available information for each variable 
are provided in the appendix (pp 19–27). Informed consent 
was obtained if necessary (depending on survey year and 
local requirement). Detailed information for each cohort is 
given in the study descriptions (appendix pp 2–11).
Procedures
Our outcome measure was the first occurrence of a 
major cardiovascular event (appendix pp 16–18). This was 
assessed in all participating individuals and death of non­
cardiovascular­disease cause was used as a competing 
risk if appropriate. We defined it as a composite endpoint 
of the first non­fatal or fatal coronary heart disease or 
ischaemic stroke event. Coronary heart disease was 
defined as a composite of non­fatal or fatal myocardial 
infarction including unstable angina, coronary death, and 
coronary revascularisation. Outcomes were measured in 
each prospective cohort study by standardised follow­up 
(visit, report, registry information, etc; details are given 
for each cohort, appendix pp 2–11). Composite endpoint 
information for current analyses is provided in the 
appendix (pp 16–18). There were no secondary outcomes.
We based our cholesterol threshold concentrations on 
the treatment­determining cholesterol categories of the 
2016 European guidelines on cardiovascular disease 
prevention.16 As recommended by the guidelines, we 
calculated non­HDL cholesterol thresholds by adding 
30 mg/dL to the LDL cholesterol thresholds defined in 
our cohorts. Our analyses were based on baseline 
information avail able for concentrations of non­HDL 
cholesterol and LDL cholesterol. We report threshold 
concentrations in mmol/L, assuming that 1 mmol/L 
contains 38·67 mg/dL of LDL cholesterol and non­HDL 
cholesterol (for non­HDL cholesterol, the following 
categories were used: <100 mg/dL [<2·6 mmol/L]; 100 to 
<145 mg/dL [2·6 to <3·7 mmol/L]; 145 to <185 mg/dL 
[3·7 to <4·8 mmol/L]; 185 to <220 mg/dL [4·8 to 
<5·7 mmol/L], and ≥220 mg/dL [≥5·7 mmol/L]). The 
cutoff between the second and third category differs 
slightly from the European guidelines. We adapted this 
cutoff from 130 mg/dL (3·4 mmol/L) to 145 mg/dL 
(3·7 mmol/L), since the latter is the goal for lipid­
lowering therapy recommended for individuals at low 
risk,4 who comprise most of our study population.
The following study variables were considered for 
analysis (but were not endpoints): age, sex, year of 
examination, body­mass index (BMI), systolic blood 
pressure, smoking status, use of cholesterol­lowering 
medication, total cholesterol, HDL cholesterol, and 
non­HDL cholesterol. History of arterial hyperten sion, 
diabetes, stroke, and myocardial infarction were defined 
as they had been documented or self­reported. Anti­
hypertensive medication, lipid­lowering medication, 
and smoking status were self­reported. For individuals 
receiving lipid­lowering therapy, baseline concentrations 
of non­HDL cholesterol and LDL cho lesterol were 
inflated by 30% for the analyses, assuming that treatment 
with statins had a moderate effect on lipid reduction and 
was initiated late during lifetime.17 Information about 
individuals receiving lipid­lowering therapy stratified by 
survey decades and age is shown in the appendix (p 28).
Statistical analysis
For each analysis, only individuals with all data available 
on the relevant variables were used. To investigate the 
association of non­HDL cholesterol concentrations and 
time to cardiovascular disease, sex­specific cumulative 
incidence curves were produced according to the defined 
baseline non­HDL cholesterol threshold concentra­
tions, with death of non­cardiovascular­disease causes as 
competing risk, using the Aalen­Johansen estimator. 
Multivariable Cox proportional hazards models were 
then computed, stratified for cohort and sex. Non­HDL 
cholesterol was coded as a categorical variable, with 
the help of dummy variables, using our predefined 
thresholds and included an interaction term with sex, 
to obtain sex­specific associations. To examine the 
association of non­HDL cholesterol across different ages, 
the models were expanded by adding an interac tion 
between age category (<45, 45–59, and ≥60 years 
at baseline) and non­HDL cholesterol. Additional Cox 
regression analyses were done to model the concen­
trations of non­HDL cholesterol as a continuous variable 
via cubic splines. All Cox models were adjusted for 
age (timescale), sex (strata), cohort (strata), and classical 
cardiovascular risk factors (smoking status, diabetes, 
BMI, systolic blood pressure, and anti hypertensive 
medication). In a sensitivity analysis, sex­specific hazard 
ratios (HRs) for non­HDL cholesterol as a categorical 
variable were estimated in each country using models 
similar to the primary analysis, and the results were 
pooled using a random­effects multivariate meta­analysis. 
Further sensitivity analyses include the computation of 
time­dependent HRs for non­HDL cholesterol to examine 
deviations from the proportional hazards assumption 
(appendix p 29).
To establish a tool to assess the probability of car­
diovascular disease by the age of 75 years, we split the 
whole data randomly into two parts of approximately 
equal size into derivation and validation datasets. In 
particular, each single cohort was part of both datasets. 
Using those observations where the required endpoint 
and covariate information was available, we developed 
a model that was calculated on the basis of cause­
specific Cox models for cardiovascular disease stratified 
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for sex and cohort. Death from non­cardiovascular­
disease causes was added as a competing risk, to account 
for the fact that an individual dying from such a cause 
before developing cardiovas cular disease will not be able 
to develop cardio vascular disease. These models used age 
as the timescale and the same variables as our previous 
Cox models. Non­HDL cholesterol, BMI, and systolic 
blood pressure were modelled using cubic splines. 
The models included an interaction between non­HDL 
cholesterol and sex. The model computation used the full 
available follow­up periods but was applied only to 
individuals aged between 35 and 70 years at baseline to 
estimate their probability of cardiovascular disease by 
the age of 75 years. These predicted probabilities were 
averaged within each combination of sex, non­HDL 
cholesterol category, age category, and according to 
whether the number of risk factors present (smoking, 
arterial hypertension, diabetes, and obesity) was greater 
than or equal to two, or less than two. We then assumed 
a reduction of the probabilities and their averages 
through a 50% or 30% reduction of non­HDL cholesterol, 
on the basis of the equation 1 – exp(–0·249 + [number 
of years of treatment–5] × [–0·0152]) for the expected 
proportional risk reduction per mmol/L in LDL choles­
terol for a given treatment duration.2 It was assumed that 
this equation was also valid for non­HDL cholesterol. 
Fol lowing the methods described by Austin,18 these 
average probabilities can then be used to estimate risk 
differences, numbers needed to treat, and differences in 
relative risk.
To obtain predicted probabilities from the cause­
specific Cox models for each combination of sex and 
cohort, the respective cause­specific baseline hazard 
function was estimated by fitting a Weibull curve to age 
and adjusting for the linear predictor of the Cox model. 
By using age as the timescale, it is possible to estimate 
the probability of an event within each combination of 
sex and cohort for the whole range of ages available in 
that part of the data. C­indices and smooth calibration 
curves were calculated for different timeframes 
separately in the derivation and validation datasets. 
The calibration curves were based on smoothing pseudo­
values calculated with the Aalen­Johansen estimate of 
cumulative incidence.19 Tenfold cross­validation was 
used in these computations.
Sensitivity analyses used time­dependent coefficients 
that were allowed to change with attained age in the 
predefined groups (<45, 45–59, and ≥60 years). To 
calculate the effect of non­HDL cholesterol reduction on 
cardiovascular risk, we assumed a reduction of baseline 
non­HDL cholesterol by 30% or 50% (adapted from 
the 2018 American College of Cardiology/American 
Heart Association Guideline on the Management of 
Blood Cholesterol).5 On the basis of this reduction, we 
recalculated the probability of a cardiovascular disease 
event by the age of 75 years, as in our predictive model. 
The models and their averaged predictions were calcu­
lated in the derivation cohorts and also independently in 
the validation cohorts, and the discrepancy between the 
average predictions was compared using the root mean 
square error. This last step was repeated using the 
complete dataset, excluding each country in turn and 
also in the excluded country, thus generating country­
specific root mean square errors. The final models and 
their predictions were computed in the complete dataset. 
Cumulative inci dence curves for specific combinations 
of variables were produced on the basis of the 
cause­specific Cox models. Here, we also assumed a 
50% reduction in non­HDL cholesterol for the included 
individuals. Applying this equation for the expected 
proportional risk reduction for a given treatment 
duration could yield a non­monotonic curve. Therefore, 
Examination 
years
Examination 
age (years)
Age 
<45 years 
Age 
45–59 years 
Age 
≥60 years 
Female SCORE PCE BMI 
(kg/m²)
Hypertension Diabetes Daily 
smoker
All 
(n=398 846)
1970–2013 51·0 
(40·7–59·7)
118 731 
(32·9%)
179 265 
(42·8%)
100 842   
(24·3%)
184 055  
(48·7%)
1·0  
(0·2–3·6)
4·3  
(1·2–11·4)
25·7 
(23·1–28·8)
162 632   
(40·1%)
18 656 
(4·8%)
130 940   
(33·3%)
Numbers 
available
377 596 
(95·3%)
398 838 
(>99·9%)
398 838 
(>99·9%)
398 838 
(>99·9%)
398 838 
(>99·9%)
398 846 
(100·0%)
357 911 
(81·4%)
277 278 
(62·7%)
395 505 
(99·2%)
388 941 
(97·8%)
384 164 
(96·5%)
387 447 
(97·4%)
Derivation 
(n=199 415)
1970–2013 51·0 
(40·9–59·7)
59 387 
(32·5%)
89 676   
(43·1%)
50 348  
(24·4%)
91 786   
(48·4%)
1·0  
(0·2–3·6)
4·3  
(1·2–11·4)
25·8 
(23·1–28·8)
81 279   
(40·3%)
9245  
(4·8%)
65 640  
(33·8%)
Numbers 
available
188 767 
(95·2%)
199 411 
(>99·9%)
199 411 
(>99·9%)
199 411 
(>99·9%)
199 411 
(>99·9%)
199 415 
(100·0%)
178 980 
(82·0%)
138 663 
(63·3%)
197 767 
(99·2%)
194 534 
(97·8%)
192 097 
(96·4%)
193 708 
(97·4%)
Validation 
(n=199 431)
1970–2013 50·9 
(40·6–59·6)
59 344  
(33·3%)
89 589   
(42·5%)
50 494   
(24·2%)
92 269   
(49·1%)
1·0  
(0·2–3·6)
4·3  
(1·2–11·4)
25·7 
(23·2–28·9)
81 353   
(40·0%)
9411   
(4·7%)
65 300   
(32·8%)
Numbers 
available 
188 829 
(95·3%)
199 427 
(>99·9%)
199 427 
(>99·9%)
199 427 
(>99·9%)
199 427 
(>99·9%)
199 431 
(100·0%)
178 931 
(80·9%)
138 615 
(62·2%)
197 738 
(99·2%)
194 407 
(97·8%)
192 067 
(96·6%)
193 739 
(97·5%)
p value 0·51 0·63 0·49 0·44 0·66 0·43 0·85 0·76 0·85 0·70 0·66 0·19
Data are n (%) for numbers available, median (IQR) for continuous variables (except for examination years where the range is given), n (%) of participants or % (95% CI) for categorical variables. p values are given 
for the validation cohort versus the derivation cohort using weighted versions of the Mann-Whitney and χ² test. Due to the presence of the Estonian case-cohort dataset, the summary estimates (% and median 
[IQR]) are weighted by the inverse of the inclusion probability for individuals in that cohort. The individuals from other cohorts are given weight 1 in the computation. Totals (n) are not weighted. From the 
Estonian data only, the sub-cohort is used in the table computations. SCORE=Systematic Coronary Risk Estimation. PCE=Pooled Cohort Equations. BMI=body-mass index. 
Table 1: Weighted baseline characteristics of the study population including derivation and validation datasets
Articles
www.thelancet.com   Vol 394   December 14, 2019 2177
the resulting curves were forced to remain constant in 
the event of a decrease.
To compare the discrimination of a model using non­
HDL cholesterol with that of a model using LDL 
cholesterol, additional cause­specific Cox models were 
computed using age as the timescale, sex and cohort as 
strata, adjusting for cardiovascular risk factors (smoking 
status, diabetes, BMI, systolic blood pressure, and 
antihypertensive medication), and including a sex–lipid 
variable interaction. All continuous variables, except age, 
were modelled using cubic splines. Tenfold cross­vali­
dation was used when computing the C­indices. The main 
analyses for non­HDL cholesterol were repeated for 
LDL cholesterol. All statistical methods were implemented 
in R statistical software, version 3.6.1.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing 
of the report. The corresponding author (SB) and the 
lead statistician (FO) had full access to all the data in 
the study, and the corresponding author had final 
responsibility for the decision to submit for publication.
Results
We identified 38 co horts reporting on 398 846 individuals 
with 5 604 735 person­years of follow­up data available for 
analysis, of whom 184 055 (48·7%) were women (tables 1 
and 2, appendix pp 19–27, 30). Examination years ranged 
from 1970 to 2013 (years for each cohort are given in the 
appendix pp 19–27). We included 199 415 individuals 
in the derivation cohort (91 786 [48·4%] women) and 
199 431 (92 269 [49·1%] women) in the validation cohort. 
The median age of participants was 51·0 years 
(IQR 40·7–59·7). 12 311 (4·9%) were receiving lipid­
lowering therapy. Median follow­up time was 13·5 years 
(IQR 7·0–20·1) with a maximum follow­up of 43·6 years.
54 542 cardiovascular disease endpoints (37 888 in 
men, 16 654 in women; 27 185 in the derivation cohort, 
27 357 in the validation cohort) occurred throughout 
the follow­up period. The predefined thresholds of 
non­HDL choles terol concentrations strongly differen­
tiated cardiovascular disease risk, particularly beyond 
 Cholesterol-
lowering 
medication
LDL cholesterol 
(mmol/L) 
HDL cholesterol 
(mmol/L) 
Non-HDL 
cholesterol 
(mmol/L) 
Non-HDL cholesterol categories
<2·6 mmol/L 2·6 to 
<3·7 mmol/L
3·7 to 
<4·8 mmol/L
4·8 to 
<5·7 mmol/L
≥5·7 mmol/L
All  
(n=398 846)
12 311  
(4·9%)
3·6  
(2·9–4·3)
1·3  
(1·1–1·6)
4·3  
(3·5–5·2)
16 572  
(5·1%)
85 811  
(26·2%)
109 270  
(33·3%)
67 099  
(20·4%)
49 575  
(15·1%)
Numbers 
available
247 733 
(59·7%)
264 999 
(60·1%)
328 517 
(74·4%)
328 327 
(74·3%)
328 327 
(74·3%)
328 327 
(74·3%)
328 327 
(74·3%)
328 327 
(74·3%)
328 327 
(74·3%)
Derivation 
(n=199 415)
6081  
(4·9%)
3·6  
(2·9–4·3)
1·3  
(1·1–1·6)
4·3  
(3·5–5·2)
8194  
(5·1%)
42 941 
(26·2%)
54 771  
(33·4%)
33 463  
(20·3%)
24 804  
(15·1%)
Numbers 
available
123 904 
(60·3%)
132 424 
(60·5%)
164 276 
(75·0%)
164 173 
(74·9%)
164 173 
(74·9%)
164 173 
(74·9%)
164 173 
(74·9%)
164 173 
(74·9%)
164 173 
(74·9%)
Validation 
(n=199 431)
6230  
(5·0%)
3·6  
(2·9–4·3)
1·3  
(1·1–1·6)
4·3  
(3·5–5·2)
8378  
(5·1%)
42 870  
(26·2%)
54 499  
(33·2%)
33 636  
(20·4%)
24 771  
(15·0%)
Numbers 
available
123 829 
(59·0%)
132 575 
(59·6%)
164 241 
(73·8%)
164 154 
(73·7%)
164 154 
(73·7%)
164 154 
(73·7%)
164 154 
(73·7%)
164 154 
(73·7%)
164 154 
(73·7%)
p value 0·18 0·79 0·01 0·79 0·85 0·99 0·58 0·29 0·64
Data are n (%) for numbers available, median (IQR) for continuous variables, n (%) of participants or % (95% CI) for categorical variables. p values are given for the validation 
cohort versus the derivation cohort using weighted versions of the Mann-Whitney and χ² test. Due to the presence of the Estonian case-cohort dataset, the summary estimates 
(% and median (IQR)) are weighted by the inverse of the inclusion probability for individuals in that cohort. The individuals from other cohorts are given weight 1 in the 
computation. Totals (n) are not weighted. From the Estonian data only, the sub-cohort is used in the table computations. 
Table 2: Weighted baseline characteristics for cholesterol-related measures
Figure 1: Incidence of cardiovascular disease across non-HDL cholesterol thresholds
Cumulative incidence curves and numbers at risk for incident fatal and non-fatal cardiovascular disease according 
to non-HDL cholesterol concentration categories in women and men. Death from non-cardiovascular-disease 
causes was used as competing risk. p values are given for Gray’s test comparing cumulative incidence curves.
Number at risk
≥5·7 mmol/L
4·8 to <5·7 mmol/L
3·7 to <4·8 mmol/L
2·6 to <3·7 mmol/L
<2·6 mmol/L
0
19 101
26 054
47 516
46 249
10 216
10
11 502
15 534
28 175
27 712
5801
20
3758
5374
10 061
10 299
2034
30
39
104
395
1005
321
Follow-up (years) 
0
25
50
75
100
0
29 955
40 190
60 083
37 918
5878
10
17 871
24 087
34 694
20 743
2940
20
4036
5605
8810
5798
895
30
349
358
703
597
129
Follow-up (years) 
Women Men
Cu
m
ul
at
iv
e 
ca
rd
io
va
sc
ul
ar
 d
ise
as
e 
in
cid
en
ce
 (%
)
≥5·7 mmol/L
4·8 to <5·7 mmol/L
3·7 to <4·8 mmol/L
2·6 to <3·7 mmol/L
<2·6 mmol/L
Non-HDL cholesterol
p <0·0001 p <0·0001
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10 years, even in the lowest cholesterol categories 
(figure 1). The cumulative incidence curves showed 
a stepwise increase of cardio vascular disease events 
across increasing concentra tions of non­HDL choles­
terol. 30­year cardiovascular disease event rates were 
approximately three­to­four times higher in women 
and men in the highest non­HDL cholesterol category 
(≥5·7 mmol/L) than those in the lowest category 
(<2·6 mmol/L; 3253 [33·7%] vs 262 [7·7%] in women 
and 7689 [43·6%] vs 375 [12·8%] in men). Multivariable 
analyses confirmed a strong continuous association of 
concentrations of non­HDL cholesterol with the sex­
specific cardiovascular disease risk. The lowest hazard 
for cardiovascular disease was found in women and 
men with the lowest non­HDL cholesterol concen­
trations, whereas there was a continuous and linear 
increase for higher non­HDL cholesterol concentrations 
(figure 2; the reference value [HR 1·0] was set as 
2·6 mmol/L non­HDL cholesterol in both women and 
men). The hazard of car diovascular disease increased 
progressively with higher non­HDL cholesterol 
categories compared with the reference category 
(figure 3). This association remained consistent in a 
sensitivity analysis using a random­effects multivariate 
meta­analysis (appendix p 31). The steepest increase of 
the relative hazard associated with non­HDL cholesterol 
was found in individuals younger than 45 years at 
Figure 2: Sex-specific continuous association of non-HDL cholesterol and 
cardiovascular disease
Sex-specific linear association of non-HDL cholesterol and cardiovascular disease 
risk (winsorised at 1·6 and 8·5 mmol/L). The Cox model used is adjusted for age, 
sex, study cohort, smoking, diabetes, body-mass index, systolic blood pressure, 
and antihypertensive medication. Non-HDL cholesterol was modelled using 
cubic splines. An interaction between sex and non-HDL cholesterol was included 
in the model. Median follow-up was 12·8 (IQR 7·5–18·4) years.
3 5 7
0·7
1·0
1·3
1·8
2·4
3·2
H
az
ar
d 
ra
tio
Non-HDL cholesterol (mmol/L)
Women
Men
Figure 3: Age-specific and sex-specific association of non-HDL cholesterol and cardiovascular disease
Lifetime sex-specific HRs for fatal and non-fatal cardiovascular disease (reference non-HDL cholesterol <2·6 mmol/L) in the overall cohort and according to three age 
categories (p<0·001 for the interaction of age and non-HDL cholesterol categories in women and in men). The Cox regression models were adjusted for age at 
baseline, sex, study cohort, smoking, diabetes, body-mass index, systolic blood pressure, and antihypertensive medication. HR=hazard ratio.
HR (95% CI)
Women Men
Events (n) Events (n) HR (95% CI)
All
<2·6 mmol/L
2·6 to <3·7 mmol/L
3·7 to <4·8 mmol/L
4·8 to <5·7 mmol/L
≥5·7 mmol/L
<45 years
<2·6 mmol/L
2·6 to <3·7 mmol/L
3·7 to <4·8 mmol/L
4·8 to <5·7 mmol/L
≥5·7 mmol/L
45–59 years
<2·6 mmol/L
2·6 to <3·7 mmol/L
3·7 to <4·8 mmol/L
4·8 to <5·7 mmol/L
≥5·7 mmol/L
≥60 years
<2·6 mmol/L
2·6 to <3·7 mmol/L
3·7 to <4·8 mmol/L
4·8 to <5·7 mmol/L
≥5·7 mmol/L
Reference
1·1 (1·0–1·3)
1·4 (1·2–1·6)
1·6 (1·4–1·8)
1·9 (1·6–2·2)
Reference
1·2 (0·9–1·6)
1·8 (1·3–2·4)
2·6 (1·8–3·6)
4·3 (3·0–6·1)
Reference
1·0 (0·8–1·3)
1·4 (1·1–1·7)
1·7 (1·4–2·2)
2·3 (1·8–2·9)
Reference
1·1 (0·9–1·4)
1·2 (0·9–1·4)
1·3 (1·0–1·6)
1·4 (1·1–1·7)
244
1762
3323
2780
3079
49
245
259
140
106
86
605
1156
992
1131
109
912
1908
1648
1842
307
2646
5882
5060
4959
35
330
675
634
627
109
976
2532
2403
2733
163
1340
2675
2023
1599
Reference
1·1 (1·0–1·3)
1·4 (1·2–1·6)
1·7 (1·5–2·0)
2·3 (2·0–2·5)
Reference
1·4 (1·0–2·0)
2·0 (1·4–2·8)
3·2 (2·3–4·5)
4·6 (3·3–6·5)
Reference
1·0 (0·8–1·2)
1·3 (1·1–1·5)
1·6 (1·3–1·9)
2·1 (1·8–2·6)
Reference
1·1 (1·0–1·4)
1·3 (1·1–1·6)
1·5 (1·3–1·8)
1·8 (1·5–2·2)
0·40 0·70 1·00 1·40 2·00 3·00 4·50 7·00
Negative association Positive association
0·40 0·70 1·00 1·40 2·00 3·00 4·50 7·00
Negative association Positive association
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baseline (maximum HR 4·3, 95% CI 3·0–6·1 in women 
and 4·6, 3·3–6·5 in men, for non­HDL cholesterol 
≥5·7 mmol/L). Within the older groups, the association 
of non­HDL cholesterol with incident cardio vascular 
disease was attenuated but still detectable in individuals 
aged 60 years and older (HR 1·4, 95% CI 1·1–1·7 
in women and 1·8, 1·5–2·2 in men, for non­HDL 
cholesterol ≥5·7 mmol/L; p<0·001 for the inter action of 
age and non­HDL cholesterol categories in women and 
in men; figure 3). Similar results were found in 
sensitivity analyses excluding individuals with diabetes 
(appendix p 38) and those receiving lipid­lowering 
therapy (appendix p 39) at baseline. The associ ation 
of non­HDL cholesterol and cardiovascular disease 
remained consistent after addi tionally adjusting for 
HDL cholesterol (appendix p 40).
We found similar results for the association of blood 
concentrations of LDL cholesterol and incident cardio­
vascular disease to non­HDL cholesterol (appendix p 32). 
Cardiovascular disease event rates increased stepwise 
with increasing LDL cholesterol categories (appendix 
p 41). Multivariable analyses showed a linear association 
of LDL cholesterol with cardiovascular disease on 
the log­hazard scale, with the lowest relative risk for 
cardio vascular disease in the individuals with the 
lowest LDL cholesterol concentrations (appendix p 42). 
The strongest association was detected in individuals 
younger than 45 years and was attenuated in individuals 
aged 60 years and older (p<0·001 for the interaction of 
age and LDL cholesterol category in women and in men; 
appendix p 43).
To estimate the long­term probability of a car­
diovascular disease event associated with non­HDL 
cholesterol, we established a model for cardiovascular 
disease risk up to the age of 75 years on the basis of a 
derivation–vali dation approach. Besides the non­HDL 
cholesterol category, sex, age, and the baseline number 
(≤1 vs ≥2) of classical modifiable cardiovascular risk 
factors (ie, arterial hypertension, dia betes, obesity, and 
smoking) were incorporated into this model (figure 4). 
For example, women with non­HDL cholesterol concen­
trations between 3·7 and 4·8 mmol/L, younger than 
45 years, and with at least two additional cardiovascular 
risk factors had a 15·6% (95% CI 14·9–16·6) probability 
of experiencing a non­fatal or fatal cardiovascular disease 
event by the age of 75 years (28·8%, 28·1–29·5 in men 
with the same character istics). The highest long­term 
risk of cardiovascular disease was seen in individuals 
younger than 45 years of age. The risk predictions 
obtained from this model were highly comparable in 
the derivation and validation datasets with a root mean 
square error lower than 1% for the estimated probabil­
ities of cardiovascular disease (appendix p 44). Country­
specific root mean square errors, as well as C­indices 
and smooth calibration curves specific for sex and 
follow­up time are provided in the appendix (pp 33, 34, 45). 
Further sensitivity analyses using time­dependent 
HRs did not show relevant differences in the prediction 
of cardiovascular disease by the age of 75 years 
(appendix p 46).
We calculated the optimally achievable risk reduction 
for cardiovascular disease by the age of 75 years 
Figure 4: Model of long-term cardiovascular disease risk prediction and the benefit of lipid reduction
Individual risk of fatal or non-fatal cardiovascular disease in women (A) and men (B) according to age, non-HDL cholesterol concentration, and the number of 
additional cardiovascular risk factors (daily smoking, arterial hypertension, diabetes, and obesity; white circle). The red circle represents the probability (%) of 
cardiovascular disease by the age of 75 years. The hypothetically achievable probability (%) for cardiovascular disease by the age of 75 years after 50% reduction of 
non-HDL cholesterol is given in the green circle. Corresponding 95% CIs are provided in the appendix (p 37).
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assuming a 50% reduction of non­HDL cholesterol 
(figure 4). In the population with non­HDL cholesterol 
of 3·7–4·8 mmol/L, younger than 45 years, and with 
at least two risk factors, the long­term risk of 
cardiovascular disease could hypo thetically be reduced 
from 15·6% (95% CI 14·9–16·6) to 3·6% (3·4–3·8) in 
women and from 28·8% (28·1–29·5) to 6·4% (6·3–6·6) 
in men. Further, corresponding numbers of patients 
needed to treat over the lifespan up to the age of 
75 years, and achievable relative risk reduction (RRR) 
are shown in table 3. For example, in the same 
individuals, the number needed to treat to reduce one 
cardiovascular disease event over the lifespan by the 
age of 75 years was 8·3 in women and 4·5 in men, 
with RRR of 77% in women and 78% in men (see 
appendix p 35 for estimates with a 30% reduction of 
non­HDL cholesterol). Additionally, we computed the 
incidence for cardiovascular disease and the achievable 
risk reduction due to 50% reduction of non­HDL 
cholesterol for specific individuals starting at different 
ages. Absolute risk reductions of cardiovascular disease 
were more pronounced in individuals with two or 
more cardiovascular disease risk factors than in those 
with one or no risk factors, and in men than women. 
Within each category, the greatest effect was found for 
the youngest individuals (appendix pp 36, 47).
Discussion
Using individual­level data from the Multinational 
Cardiovascular Risk Consortium of individuals without 
prevalent cardiovascular disease, we characterised the 
age­specific and sex­specific long­term association of non­
HDL cholesterol with cardiovascular disease. On the 
basis of this association, we derived and validated a tool 
specific for age, sex, and cardiovascular risk factors to 
assess the individual long­term probability of cardio­
vascular disease by the age of 75 years associated with 
non­HDL cho lesterol. Further, we modelled the poten­
tially achievable long­term cardiovascular disease risk, 
assuming a 50% reduction of non­HDL cholesterol.
The proatherogenic effects of apoB­containing lipopro­
teins are largely based on the development and progression 
of atherosclerotic plaques and by accumulation of these 
lipoproteins within the arterial intima.20,21 Although the 
measurement of LDL cholesterol can be influenced by 
increased triglycerides22,23 in cardiovascular risk assess­
ment, an appropriate way to estimate the amount of apoB­
containing lipoproteins is the determination of non­HDL 
cholesterol.3,21,24,25 Therefore, our main analyses are based 
on non­HDL cholesterol. In line with previous studies, 
we found a comparable prognostic relevance for non­
HDL cholesterol and LDL cholesterol.26 A large body of 
evidence including inherited disorders,27 genetic28,29 
and epidemiological studies,10,11 and clinical trials7–9 leads 
to the hypothesis that reducing apoB­containing lipo­
proteins, regardless of the method, should yield a 
corresponding reduction in cardiovascular events. To 
intervene early and intensively during the lifespan 
might even lead to regression of early manifestation of 
atherosclerosis.30 Epidemiological studies have shown 
the association between cholesterol concentration and 
cardiovascular mortality during long­term follow­up.11,31 
Furthermore, repeated non­HDL cholesterol testing in 
2516 individuals of the Framingham Offspring Study 
suggested that stable concentrations over the lifetime13 
might represent increased risk of cardiovascular disease. 
Clinical trials, however, mostly address older (age 
>60 years for most studies) individuals with prevalent 
cardiovascular disease or at markedly increased cardio­
vascular risk and report obser vations over short follow­up 
intervals, varying between 2 and 7 years.7–9
Considerable uncertainty exists about the extent to 
which slightly increased or apparently normal cholesterol 
concentrations affect lifetime cardiovascular risk and 
about which thresholds should be used to merit a treat­
ment recommendation, particularly in young people. 
Our study extends current knowledge because it suggests 
that increasing concentrations of non­HDL cholesterol 
predict long­term cardiovascular risk, particularly in 
cases of modest increase at a young age. Only a few 
studies have reported the age­dependent association of 
lipids and cardiovascular disease with focus on young 
individuals.10,11,13 In our analyses, individuals younger 
than 45 years showed the strongest HRs for the 
<2·6 mmol/L 2·6 to 
<3·7 mmol/L
3·7 to 
<4·8 mmol/L
4·8 to 
<5·7 mmol/L
≥5·7 mmol/L
NNT RRR NNT RRR NNT RRR NNT RRR NNT RRR
Women
<45 years
0–1 32·0 0·55 21·2 0·68 14·8 0·77 11·0 0·83 8·1 0·89
≥2 15·3 0·53 11·0 0·68 8·3 0·77 6·7 0·83 4·6 0·90
45–59 years
0–1 38·8 0·46 25·3 0·59 18·1 0·67 13·7 0·73 9·7 0·80
≥2 19·8 0·45 13·5 0·58 10·3 0·67 8·1 0·73 5·6 0·81
≥60 years
0–1 63·4 0·32 40·2 0·43 28·9 0·52 20·8 0·59 13·8 0·68
≥2 36·0 0·31 23·8 0·43 16·3 0·52 12·3 0·59 8·3 0·68
Men
<45 years
0–1 15·5 0·55 9·7 0·69 6·8 0·78 5·1 0·84 3·8 0·89
≥2 9·6 0·55 6·0 0·69 4·5 0·78 3·6 0·84 2·6 0·90
45–59 years
0–1 21·4 0·44 13·1 0·58 9·1 0·67 6·7 0·74 4·5 0·82
≥2 12·2 0·42 7·6 0·57 5·6 0·66 4·3 0·73 3·0 0·82
≥60 years
0–1 39·8 0·32 23·3 0·43 15·7 0·52 11·4 0·59 7·6 0·68
≥2 20·6 0·31 13·5 0·43 9·2 0·52 6·9 0·59 4·7 0·68
Sex-specific and age-specific estimated NNT to avoid one cardiovascular disease event and RRR for cardiovascular 
disease by age 75 years. The model used is assuming a hypothetical 50% reduction of non-HDL cholesterol. 
NNT=numbers needed to treat. RRR=relative risk reduction.
Table 3: Numbers needed to treat and RRR by age group and number of comorbid risk factors for 
non-HDL cholesterol concentration categories
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association of blood lipids with the incidence of cardiovas­
cular disease during long­term follow­up. This effect is 
probably related to the following considerations: (1) the 
effect of lifetime accumulation of proatherogenic lipids 
in the vulnerable period of the fourth and fifth decades 
of life,32 (2) the shorter timespan that individuals aged 
60 years and older have to achieve the cardiovascular 
disease endpoint due to their age itself, and (3) the fact 
that people with prevalent cardiovascular disease are not 
included in our study and thus individuals who reach 
the age of 60 without prevalent cardiovascular disease are 
a population enriched with protective charac teristics 
against the proatherogenic effect of cholesterol. However, 
although there is a weaker association of non­HDL 
cholesterol with cardiovascular disease in older indi­
viduals (>60 years), these people are at higher absolute 
risk than young individuals, and so the more modest 
relative risks represent large absolute risk differences 
across non­HDL cholesterol categories.10
The risk circle tool displays the individual lifetime risk 
of non­fatal and fatal cardiovascular disease by the age of 
75 years that is associated with non­HDL cholesterol 
and is specific for the burden of age, sex, and risk factor. 
It also estimates the corresponding risk reduction from 
lipid­lowering therapies. The risk scores currently used 
for decision making about lipid­lowering intervention 
assess only the 10­year cardiovascular risk33,34 and there­
fore underestimate lifetime risk, particularly in young 
individuals.11,12 Pencina and colleagues31 esti mated the 
30­year risk of cardiovascular disease in the Framingham 
Offspring cohort and showed 30­year risks that were up 
to ten times higher than the projected 10­year risks 
in young people.31 Therefore, in young individuals, 
the long­term risk of cardiovascular disease should 
constitute the basis of primary prevention. Since the risk 
factor burden is incorporated as a categorical variable in 
our model, we cannot provide a weighting among the 
different risk factors or a quantitative con sideration of 
every single risk factor as do other risk models. Instead, 
because of its simplicity, our risk circle tool provides an 
opportunity to estimate lifetime risks based on non­
HDL cholesterol in an accessible and easily understood 
way that can improve physician–patient communication 
about preventive strat egies in clinical practice. The 
modelled risk reduction is calculated hypothetically and 
is based on a 50% lipid reduction leading to a decrease 
of the cumulative burden of non­HDL cholesterol. Since 
the calculated numbers needed to treat are based on 
different timeframes for different age ranges, they have 
to be compared carefully between the different age 
categories. They have to be interpreted individually for 
a certain spectrum of ages, sexes, and risk factors to 
guide decision making on any lipid­lowering inter­
vention. Furthermore, numbers needed to treat might 
be higher than those we showed in low­risk countries 
with lower than average cardiovascular disease incidence 
and mortality.
The following limitations merit consideration. First, 
due to the population­based longitudinal study design, 
the endpoint information is mainly based on medical 
reports or local registers and we cannot exclude mis­
classification of endpoints for some of the observed 
effects. However, endpoint information was harmo­
nised on the basis of individual data according to the 
specification of the MORGAM study, and multivariable 
analyses were adjusted for potential confounders. 
Therefore, the best achievable data quality can be 
assumed for the current analyses. Second, only baseline 
data of blood lipids were available for current analyses. 
No information about dynamic changes during follow­
up or about the initiation of lipid­lowering therapy, 
particularly in those individuals with very high blood 
concentrations, could be considered.35 However, non­
HDL cholesterol concentrations in young individuals 
are generally stable over the 30­year life course,13 and 
not adjusting for changes in risk factors was shown to 
have little bearing on lifetime cardiovascular disease 
risk.31 Third, our cohorts largely included individuals 
with European ancestry from high­income countries in 
Europe, North America, and Australia. The general­
isability of our findings to other regions or individuals 
from other racial and ethnic groups is unknown. Finally, 
the therapeutic benefit of lipid­lowering intervention 
investigated in our study is based on a hypothetical 
model that assumes a stable reduction of non­HDL 
cholesterol. We recognise that making such an assump­
tion posits that treatment effects are sustained over 
a much longer term than has been studied in clinical 
trials and that real­world benefits of taking statins are 
probably lower than those shown in trials because of 
adherence and side­effects.36 However, since clinical 
trials investigating the benefit of lipid­lowering therapy 
in individuals younger than 45 years during a follow­
up of 30 years are not available, our study provides 
unique insights into the benefits of a potential early 
intervention in primary prevention. We agree with 
Hippisley­Cox and colleagues37 that future research 
needs to address many related questions, including 
whether intervention in young people with a high 
lifetime risk but low 10­year risk would yield greater 
benefits than late intervention.
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